Literature DB >> 6089953

Parkinson's disease: depletion of substantia nigra neurotensin receptors.

G R Uhl, P J Whitehouse, D L Price, W W Tourtelotte, M J Kuhar.   

Abstract

Neurotensin receptor autoradiography reveals dense binding in normal human substantia nigra. In nigra from patients with Parkinson's disease, nigral receptor binding is only about one-third of control values. 'Saturation' analysis suggests that these changes result from receptor loss. These results support a neurotensin-dopamine interaction in human nigro-striatal circuits.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6089953     DOI： 10.1016/0006-8993(84)90935-1

Source DB:  PubMed          Journal:  Brain Res        ISSN： 0006-8993            Impact factor:   3.252


  9 in total

Review 1.  The role of neurotensin in central nervous system pathophysiology: what is the evidence?

Authors:  Fannie St-Gelais; Claudia Jomphe; Louis-Eric Trudeau
Journal:  J Psychiatry Neurosci       Date:  2006-07       Impact factor: 6.186

2.  Visualizing receptors for neurotransmitters in the human brain with autoradiography.

Authors:  J M Palacios; G Chinaglia; A Probst
Journal:  Neurosurg Rev       Date:  1989       Impact factor: 3.042

Review 3.  Regulatory peptide receptors: visualization by autoradiography.

Authors:  J M Palacios; M M Dietl
Journal:  Experientia       Date:  1987-07-15

4.  Dopaminergic control of 125I-labeled neurotensin binding site density in corticolimbic structures of the rat brain.

Authors:  D Herve; J P Tassin; J M Studler; C Dana; P Kitabgi; J P Vincent; J Glowinski; W Rostene
Journal:  Proc Natl Acad Sci U S A       Date:  1986-08       Impact factor: 11.205

Review 5.  Neuroprotective Effects of Brain-Gut Peptides: A Potential Therapy for Parkinson's Disease.

Authors:  Dong Dong; Junxia Xie; Jun Wang
Journal:  Neurosci Bull       Date:  2019-07-08       Impact factor: 5.203

6.  Human serum Cohn fraction IV (alpha-globulin [correction of globin] enriched) inhibits ligand binding at neurotransmitter receptors in human brain.

Authors:  A C Andorn; M A Pappolla; H Fox; F K Klemens; P A Martello
Journal:  Proc Natl Acad Sci U S A       Date:  1986-06       Impact factor: 11.205

Review 7.  Demystifying the Neuroprotective Role of Neuropeptides in Parkinson's Disease: A Newfangled and Eloquent Therapeutic Perspective.

Authors:  Tapan Behl; Piyush Madaan; Aayush Sehgal; Sukhbir Singh; Hafiz A Makeen; Mohammed Albratty; Hassan A Alhazmi; Abdulkarim M Meraya; Simona Bungau
Journal:  Int J Mol Sci       Date:  2022-04-20       Impact factor: 6.208

8.  Preventive Effect of Two New Neurotensin Analogues on Parkinson's Disease Rat Model.

Authors:  Maria Lazarova; Andrey Popatanasov; Radoslav Klissurov; Svetlana Stoeva; Tamara Pajpanova; Reni Kalfin; Lyubka Tancheva
Journal:  J Mol Neurosci       Date:  2018-10-30       Impact factor: 3.444

9.  Neurotensin-polyplex-mediated brain-derived neurotrophic factor gene delivery into nigral dopamine neurons prevents nigrostriatal degeneration in a rat model of early Parkinson's disease.

Authors:  Nancy G Hernandez-Chan; Michael J Bannon; Carlos E Orozco-Barrios; Lourdes Escobedo; Sergio Zamudio; Fidel De la Cruz; Jose L Gongora-Alfaro; Juan Armendáriz-Borunda; David Reyes-Corona; Armando J Espadas-Alvarez; Yazmin M Flores-Martínez; Jose Ayala-Davila; Maria E Hernandez-Gutierrez; Lenin Pavón; Refugio García-Villegas; Rasajna Nadella; Daniel Martinez-Fong
Journal:  J Biomed Sci       Date:  2015-07-22       Impact factor: 8.410
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.